top of page
MB synapse background.jpg

Developing next-generation therapies
to treat neurological disorders

Our fine-tuned drug design approach enables us to precisely treat neurological disorders like Essential Tremor, epilepsy and anxiety by restoring healthy brain receptor function, without overactivating

Vision
Pagliuca Harvard Life Lab.jpeg

Pagliuca
Harvard
Life Lab

OUR STORY

Our team has dedicated their careers to developing neuro-medicines for patients. We coalesced to advance scientific innovations that help patients with neurological disorders live longer, healthier lives.

The idea was born at Prof. Kevin Hodgetts' Laboratory for Drug Discovery in Neuroscience at the Brigham and Women's Hospital, when Dr. Hodgetts and Dr. Dario Doller saw the opportunity to harness allosteric modulation to develop a new generation of neurological therapies.

We are now advancing a small molecule therapy to treat Essential Tremor (ET), then targeting epilepsy, anxiety, and other neurological disorders.
 

Our unique methodology

brain.png

Next-generation

We are developing advanced positive allosteric modulators, building on decades of research in the space, to provide improved medicines in neurology and psychiatry. 

Precise

We control for risk by focusing on validated biological targets, with strong translational assays and efficient route to clinical proof-of-mechanism where current treatments fail to address patient needs.

Patients First

Our lead small molecule is a GABAA modulator, fine-tuned to restore healthy receptor function while avoiding over-activation, to provide efficacy with reduced side-effects

check mark.png
science.png

Our Therapy

We have achieved in vivo proof-of-concept in mice, and are now identifying a development candidate to treat Essential Tremor.

Brain Scans

Meet the Team

We have dedicated our careers to advancing scientific innovations to help patients live longer, healthier lives.

Our Scientific Advisory Board

Our SAB is deeply involved in all aspects of Modulate Bio. These industry veterans are committed to efficiently advancing our compounds to human trials

Recognitions

pillar vc_edited.png

Nucleate Venture Prize

Awarded pre-seed funding from Pillar VC via NVP, 1 of 200 teams

blavatnik HMS logo.png

Blavatnik Therapeutics Grant

Founding lab supported by Blavatnik grant funding for this project from 2022-2024

NVC.jpg

Harvard Business School

Semi-finalists in the 2023 HBS NVC pitch competition

nucleate logo.png

Nucleate Activator Program

Semi-finalists in the 2023 Nucleate Activator Program final pitch showcase in Boston

ilab.png

iLab Grant Award

Awarded grant funding by the iLab in 2023 and 2024

PIC.jpg

Harvard Innovation Lab

Semi-finalists 2023 and
Finalists 2024 in the Harvard iLab’s PIC, 5 of 400+ teams

mit ship.png

MIT SHIP Competition

Semi-finalists in the 2024 MIT SHIP competition, 8 of 300+ teams

Current treatments are worse than the disease itself

- Patients, physicians and caregivers struggling with Essential Tremor (ET)

Indication #1: Essential Tremor

Essential Tremor is widespread and highly debilitating

Yet ET remains significantly underreported and undertreated

We are thrilled to advance the first novel treatment to help ET patients, their families and caretakers in over half a century.

Please connect to learn more - we are excited to engage with the ET community!

Get in Touch

Modulate Bio

Pagliuca Harvard Life Lab 

127 Western Avenue, Allston, MA 02134

  • LinkedIn
bottom of page